New and growing evidence on the possible role of histamine in diabetes
(15 January 2018)
Due to the incidence of diabetes and the related morbidity of diabetic nephropathy, identification of new therapeutic strategies represents a health priority. Currently, renal dialysis and transplant are the only options for treatment. In the last few years new and growing evidence on the possible role of histamine in diabetes has been provided by the groups of Drs Paul Chazot (Biosciences) and Arianna Rosa (University of Turin). In particular, the histamine receptor H4R is emerging as a new promising pharmacological target for diabetic nephropathy. The aim of this study was to evaluate the efficacy of selective H4R antagonism using a clinical-lead drug on the prevention of diabetic nephropathy progression in a murine model of type-1 diabetes . Our data suggest for the first time that the H4R participates in diabetic nephropathy progression through both a direct effect on tubular reabsorption and an indirect action on renal tissue architecture via inflammatory cell recruitment. Therefore, H4R antagonism emerges as a possible new multi-mechanism therapeutic approach to counteract development of diabetic nephropathy development. Published in
Pharmacological Research (2018) 128: 18-28.